PRECISION CARE MANAGEMENT FOR PAYERS
How can you confidently approve molecular tests and targeted treatments while also minimizing burdensome prior authorization processes?
Trapelo knows.
Trapelo aligns the interests of oncologists, labs, and payers to deliver better care for patients while managing the costs of precision medicine through transparency and real-time decision support.
​
Trapelo QuickPath® signals therapies with the highest-level clinical evidence and payer integration to ensure patients get the most appropriate treatment option when time matters most.
“This is an area where aligning from the very beginning of treatment and getting the best care has to be done, because that is the most cost-effective and cost-saving way to get there.” – Dr. Caroline Carney, Chief Medical Officer, Magellan Health
Learn how Magellan Health is using the Trapelo solution with their health plan partners:
-
Read the official press release
Trapelo for Payers is:
-
Evidence-based
Assures that that each molecular test ordered through Trapelo meets clinical, evidence-supported standards, so payers can streamline and optimize their prior authorization and reimbursement arrangements.
-
Transparent
Gives payers a real-time window into the precision medicine decision-making process, enabling a review-by-exception process that avoids unnecessary administrative reviews. Trapelo streamlines workflow for practices and expedites the delivery of appropriate, quality care for patients when time matters most.
-
Patient-centered
Ensures patients get the most appropriate tests from preferred labs at the right time in their treatment journey.
-
Collaborative
Some of the nation’s leading cancer centers and community oncologists, along with national and regional molecular testing labs, have endorsed Trapelo’s innovative approach to ensuring the scalable, appropriate use of precision medicine for cancer. ​
There is a divide between the promise of precision medicine and how equitably new innovations are applied to each cancer patient’s treatment journey. Hilary Gee Goeckner and Kristine Ashcraft are actively working to close that gap as champions of the American Cancer Society's Cancer Action Network which aims to pass legislation across the US to expand insurance coverage of evidence-based biomarker testing for cancer patients. In this episode of the Precision Medicine Podcast, they explain why it’s so important.
